



PATENT

Attorney Dkt. No. 7372/72249

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): ASAKO, et al.

Appln No.: 10/004,115

Filed: December 6, 2001

Title: PROCESS FOR PRODUCING
OPTICALLY ACTIVE 4-HALO-3-
HYDROXYBUTANOATE

Group Art
Unit: 1651

Examiner: Not Yet Known

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited
with the United States Postal Service as first class mail
in an envelope addressed to: U.S. Patent and
Trademark Office, Box Sequence, P.O. Box 2327,
Arlington, VA 22202, on this date.

July 30, 02
Date

Kathleen A. Ranney
Kathleen A. Ranney
Registration No. 37,702
Attorney for Applicant(s)

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith is an amendment/reply in the above-identified application.

- ☒ Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure
- ☒ Statement Concerning Sequence Listing
- ☒ Petition for Extension of Time
- ☒ Preliminary Amendment
- ☒ Written Sequence Listing
- ☒ Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e)
- ☒ No additional fee is required.

Fee Calculation For Claims As Amended

	As Amended	Previously Paid For	Present Extra	Rate	Additional Fee
Independent Claims	0	3	** = 0	x \$ 84.00	= \$ 0.00
Total Claims	0	12	* = 0	x \$ 18.00	= \$ 0.00
Fee for Multiply Dependent Claims				\$ 280.00	
** At least 3			Total Additional Fee		\$ 0.00
* At least 20					

- ☐ A check in the amount of \$_____ is attached.
- ☐ Charge \$_____ to Deposit Account No. 06-1135.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135. Should no proper payment be enclosed herewith, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1135. A duplicate copy of this sheet is enclosed.

July 30, 2002

Date

Kathleen A. Ranney

Kathleen A. Ranney


Registration No. 37,702

FITCH, EVEN, TABIN & FLANNERY
Suite 1600
120 South LaSalle Street
Chicago, Illinois 60603-3406
Telephone: (312) 577-7000
Facsimile: (312) 577-7007

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov


APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/004,115	12/06/2001	Hiroyuki Asako	7372/72249



FITCH EVEN TABIN AND FLANNERY
120 SOUTH LA SALLE STREET
SUITE 1600
CHICAGO, IL 60603-3406

CONFIRMATION NO. 3895

FORMALITIES LETTER



0000000008198656

due 7/29/03
gm

Date Mailed: 05/29/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

*15/02
D.C.*

fehs
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY